Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Malignant Lymphoma

  Free Subscription


1 Am J Hematol
3 Blood
1 Bone Marrow Transplant
2 Br J Haematol
1 Curr Treat Options Oncol
3 Haematologica
1 Int J Radiat Oncol Biol Phys
1 J Clin Oncol
6 Leuk Lymphoma
1 N Engl J Med

  Retrieve available abstracts of this week’s articles:
HTML format
Text format
Single Articles

    Am J Hematol

  1. TISI MC, Paolini R, Piazza F, Ravelli E, et al
    Rituximab, Bendamustine and Cytarabine (R-BAC) in patients with relapsed-refractory aggressive B-cell lymphoma.
    Am J Hematol. 2018 Sep 5. doi: 10.1002/ajh.25278.
    PubMed     Text format    


  2. KATSURAGI T, Tsukada J
    Multiple subperiosteal bone resorption in adult T-cell leukemia/lymphoma.
    Blood. 2018;132:1086.
    PubMed     Text format    

    CART19 in Hodgkin lymphoma: are we driving the right model?
    Blood. 2018;132:982-983.
    PubMed     Text format    

  4. RUAN J, Martin P, Christos P, Cerchietti L, et al
    Five-year follow-up of lenalidomide plus rituximab as initial treatment for mantle cell lymphoma.
    Blood. 2018 Sep 4. pii: blood-2018-07-859769. doi: 10.1182/blood-2018-07-859769.
    PubMed     Text format     Abstract available

    Bone Marrow Transplant

  5. TSANG ES, Villa D, Loscocco F, Visani G, et al
    High-dose Benda-EAM versus BEAM in patients with relapsed/refractory classical Hodgkin lymphoma undergoing autologous stem cell transplantation.
    Bone Marrow Transplant. 2018 Aug 31. pii: 10.1038/s41409-018-0328.
    PubMed     Text format    

    Br J Haematol

  6. ANDORSKY DJ, Kolibaba KS, Assouline S, Forero-Torres A, et al
    An open-label phase 2 trial of entospletinib in indolent non-Hodgkin lymphoma and mantle cell lymphoma.
    Br J Haematol. 2018 Sep 5. doi: 10.1111/bjh.15552.
    PubMed     Text format     Abstract available

  7. JAIN P, Kanagal-Shamanna R, Zhang S, Ahmed M, et al
    Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib.
    Br J Haematol. 2018 Sep 2. doi: 10.1111/bjh.15567.
    PubMed     Text format     Abstract available

    Curr Treat Options Oncol

  8. KUMAR A, Fraz MA, Usman M, Malik SU, et al
    Treating Diffuse Large B Cell Lymphoma in the Very Old or Frail Patients.
    Curr Treat Options Oncol. 2018;19:50.
    PubMed     Text format     Abstract available


  9. GRESSIN R, Daguindau N, Tempescul A, Moreau A, et al
    A phase 2 study of rituximab, bendamustine, bortezomib and dexamethasone for first line treatment of older patients with mantle cell lymphoma.
    Haematologica. 2018 Aug 31. pii: haematol.2018.191429.
    PubMed     Text format     Abstract available

  10. EYRE TA, Walter HS, Iyengar S, Follows G, et al
    Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma post BTK inhibitor therapy.
    Haematologica. 2018 Sep 6. pii: haematol.2018.198812.
    PubMed     Text format    

  11. STRATI P, Fanale M, Oki Y, Turturro F, et al
    Rituximab with ABVD vs ABVD for advanced stage high-risk classical Hodgkin lymphoma: a randomized phase II study.
    Haematologica. 2018 Sep 6. pii: haematol.2018.199844.
    PubMed     Text format    

    Int J Radiat Oncol Biol Phys

  12. BAKST RL, Dabaja BS, Specht LK, Yahalom J, et al
    Use of Radiation in Extramedullary Leukemia/Chloroma: Guidelines From the International Lymphoma Radiation Oncology Group.
    Int J Radiat Oncol Biol Phys. 2018;102:314-319.
    PubMed     Text format     Abstract available

    J Clin Oncol

  13. EVENS AM, Advani RH, Helenowski IB, Fanale M, et al
    Multicenter Phase II Study of Sequential Brentuximab Vedotin and Doxorubicin, Vinblastine, and Dacarbazine Chemotherapy for Older Patients With Untreated Classical Hodgkin Lymphoma.
    J Clin Oncol. 2018 Sep 4:JCO2018790139. doi: 10.1200/JCO.2018.79.0139.
    PubMed     Text format     Abstract available

    Leuk Lymphoma

  14. OHNO H, Nakagawa M, Kishimori C, Fukutsuka K, et al
    A rare MYC/BCL3 double-translocation and protein-expression in a diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2018 Sep 6:1-4. doi: 10.1080/10428194.2018.1498493.
    PubMed     Text format    

  15. ISE M, Kageyama H, Araki A, Itami M, et al
    Identification of a novel GORASP2-ALK fusion in an ALK-positive large B-cell lymphoma.
    Leuk Lymphoma. 2018 Sep 6:1-5. doi: 10.1080/10428194.2018.1493731.
    PubMed     Text format    

  16. CICHOWSKA-CWALINSKA N, Dutka M, Klapkowski A, Peksa R, et al
    The role of radiotherapy in the management of primary cardiac lymphoma a case report and the literature review.
    Leuk Lymphoma. 2018 Sep 6:1-5. doi: 10.1080/10428194.2018.1509321.
    PubMed     Text format    

  17. OBR A, Prochazka V, Papajik T, Klener P Jr, et al
    Maintenance rituximab in newly diagnosed mantle cell lymphoma patients: a real world analysis from the Czech lymphoma study group registry(dagger).
    Leuk Lymphoma. 2018 Sep 6:1-8. doi: 10.1080/10428194.2018.1508672.
    PubMed     Text format     Abstract available

  18. GANZEL C, Silverman B, Chemtob D, Ben Shoham A, et al
    The risk of tuberculosis in cancer patients is greatest in lymphoma and myelodysplastic syndrome/myeloproliferative neoplasm: a large population-based cohort study.
    Leuk Lymphoma. 2018 Sep 6:1-6. doi: 10.1080/10428194.2018.1499904.
    PubMed     Text format     Abstract available

  19. UMINO K, Fujiwara SI, Minakata D, Yamamoto C, et al
    Prognostic impact of serum soluble interleukin-2 receptor level at diagnosis in elderly patients with diffuse large B-cell lymphoma treated with R-CHOP.
    Leuk Lymphoma. 2018 Sep 6:1-8. doi: 10.1080/10428194.2018.1504939.
    PubMed     Text format     Abstract available

    N Engl J Med

  20. MORSCHHAUSER F, Fowler NH, Feugier P, Bouabdallah R, et al
    Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma.
    N Engl J Med. 2018;379:934-947.
    PubMed     Text format     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Malignant Lymphoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.